The PTAB has denied institution of inter partes review of Abbvie’s U.S. Patent No. 9,114,166, finding that Petitioner Coherus had not established a reasonable likelihood that it would prevail in showing the unpatentability of the challenged claims.  The ‘166 patent is drawn to pharmaceutical formulations comprising an anti-TNFα antibody, and allegedly covers formulations of Humira® (adalimumab).  The IPR is docketed as IPR2016-01018.  We will continue to bring you updates on IPRs related to biologics and to post important documents on our IPR tracker page.